1. A significant reduction in all-cause mortality was seen among patients in the intervention group compared to usual care. 2. Over 36 months, the net group difference in systolic blood pressure was -23.1 mmHg while the difference in diastolic blood pressure was -9.9 mmHg, favouring the intervention group. Evidence Rating Level: 1 (Excellent) Study Rundown:
The global next generation immunotherapies market is estimated to exceed a spectacular valuation of US$ 268.84 billion in 2033, with a compound annual growth rate (CAGR) of 7.5% projected from 2023 to 2033. The vast majority of present immunotherapies, such as checkpoint inhibitors, seek to enhance the immune system.
The global next generation immunotherapies market is estimated to exceed a spectacular valuation of US$ 268.84 billion in 2033, with a compound annual growth rate (CAGR) of 7.5% projected from 2023 to 2033. The vast majority of present immunotherapies, such as checkpoint inhibitors, seek to enhance the immune system.
Mumbai (Maharashtra) [India], December 5 (ANI/PRNewswire): JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest-growing pharmaceutical companies in India, announced a substantial price decrease of approximately 50 per cent for the critical heart failure drug 'Azmarda'. Azmarda, which contains the patented molecule Saccubutril-Valsartan is indicated for Heart failure which ails 8 to 12 million people in the country. After the price reduction, Azmarda (Saccubutril-Valsartan), 50 mg will be available at Rs 39.6 per tablet as compared to Rs 78 per tablet. Commenting on the move, Dilip Singh Rathore, President - Domestic Business, JB Pharma, said, "Being a leading player in the cardiac segment, JB has decided to take the lead in making their Azmarda drug more accessible and affordable for heart failure patients in India. This is in line with our strategy of providing innovative and quality treatment to a larger patient pool at the most affordable price points.
Blood pressure medications may confer a significant effect if taken at night rather than in the morning and may reduce the risk of developing cardiovascular events.